Drug Characteristics
-
Formulation
100mg tablets
250mg tablets
Co formulated with lamivudine as Combivir
Co formulated with lamivudine and Abacavir as Trizivir
-
Dose
250mg twice daily
infant
Oral Term (>34 weeks): 4 mg/kg twice daily
Premature (30–34 weeks): 2 mg/kg twice daily for 2 weeks then 2 mg/kg three times a day for 2 weeks
Premature (<30 weeks): 2 mg/kg twice daily for 4 weeks
Intravenous
Term: 1.5 mg/kg four times a day
Prem: 1.5 mg/kg twice daily
-
Side Effects
myelosuppression, anaemia, nail pigmentation
-
Interactions
-
Renal
reduce oral dose to 300–400 mg daily in divided doses or intravenous dose to 1 mg/kg 3–4 times daily if eGFR is less than 10 mL/minute/1.73 m2
-
Hepatic
-
Pregnancy
FDA Pregnancy Category C status
indicated for the prevention of maternal-fetal HIV-1 transmission.
-
Other Information